Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q5H8A4

UPID:
PIGG_HUMAN

ALTERNATIVE NAMES:
GPI7 homolog; Phosphatidylinositol-glycan biosynthesis class G protein

ALTERNATIVE UPACC:
Q5H8A4; B4DKC7; Q2TAK5; Q6UX31; Q7L5Y4; Q8N866; Q8NCC9; Q96SY9; Q9BVT7; Q9NXG5

BACKGROUND:
The GPI ethanolamine phosphate transferase 2 enzyme is pivotal in the biosynthesis of glycosylphosphatidylinositol (GPI) anchors, crucial for protein localization and function on the cell surface. It specifically transfers ethanolamine phosphate to the GPI second mannose, a key step in GPI-anchor synthesis.

THERAPEUTIC SIGNIFICANCE:
Mutations in the gene encoding GPI ethanolamine phosphate transferase 2 are associated with a severe neurodevelopmental disorder, underscoring the enzyme's significance. Targeting the enzymatic activity of GPI ethanolamine phosphate transferase 2 offers a promising avenue for developing treatments for related neurological conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.